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Introduction {#ajh24256-sec-0001}
============

Acquired aplastic anemia (AA) affects both children and adults, and is characterized by low blood counts and severely hypocellular bone marrow. The underlying pathophysiology of AA is thought to be T‐cell‐mediated destruction of early hematopoietic cells [1](#ajh24256-bib-0001){ref-type="ref"}. The diagnosis of AA is made in part by excluding other disorders that can present with bone marrow failure (BMF) [2](#ajh24256-bib-0002){ref-type="ref"}.

Dyskeratosis congenita (DC) is a multisystem BMF syndrome, caused by mutations of genes involved in telomere maintenance [3](#ajh24256-bib-0003){ref-type="ref"}. Although DC classically presents in childhood with stereotypical mucocutaneous changes of skin, nails, and mucosa, milder forms of telomere dysfunction, such as those associated with mutations in *TERT* and *TERC* genes, can present with bone marrow failure indistinguishable from AA both in children and adults [4](#ajh24256-bib-0004){ref-type="ref"}. Furthermore, patients with telomere disorders, particularly those caused by *TERT* and *TERC* mutations, can present with a variety of liver abnormalities including hepatic inflammation, fibrosis, and cirrhotic liver failure [5](#ajh24256-bib-0005){ref-type="ref"}, [6](#ajh24256-bib-0006){ref-type="ref"}. In clinical practice, lymphocyte telomere length (TL) measurements are used as a first‐line screen to rule out inherited telomeropathies before initiating treatment for AA [7](#ajh24256-bib-0007){ref-type="ref"}, [8](#ajh24256-bib-0008){ref-type="ref"}.

During routine clinical screening, we observed that several patients with classic features of hepatitis‐associated AA (HAA), a subset of AA that occurs concurrent to or following an acute episode of seronegative hepatitis [9](#ajh24256-bib-0009){ref-type="ref"}, had lymphocyte TL at or below the first percentile of age‐matched controls, in the range similar to that of inherited telomere disorders [10](#ajh24256-bib-0010){ref-type="ref"}, [11](#ajh24256-bib-0011){ref-type="ref"}. To confirm our initial observation, we retrospectively analyzed TL measurements obtained at the time of diagnosis in 10 consecutively enrolled HAA patients, and compared them to TL in patients with non‐hepatitis associated AA. Our results show that a subgroup of patients with HAA present with significantly shorter TL at diagnosis, leading to a diagnostic challenge in differentiating between HAA and inherited telomeropathies based on TL measurement.

Methods {#ajh24256-sec-0002}
=======

Patients and study oversight {#ajh24256-sec-0003}
----------------------------

The Children\'s Hospital of Philadelphia (CHOP) Bone Marrow Failure Syndrome (BMFS) cohort is an open prospective/retrospective cohort for the study of molecular mechanisms of BMFS, approved by the CHOP Institutional Review Board. Written informed consent from all study participants or their legal guardians was obtained prior to study participation in accordance with the Declaration of Helsinki. All consecutively enrolled patients with pediatric‐onset AA, referred to the CHOP Comprehensive BMFS Center between 2009 and 2015, who had clinical telomere length (TL) measurement within 6 months of diagnosis and prior to therapy initiation, were eligible for this analysis. The diagnosis of AA and disease severity classification were made according to previously published criteria, and required exclusion of inherited BMFS [12](#ajh24256-bib-0012){ref-type="ref"}, [13](#ajh24256-bib-0013){ref-type="ref"}. HAA was defined according to established criteria [9](#ajh24256-bib-0009){ref-type="ref"}, [14](#ajh24256-bib-0014){ref-type="ref"} as severe bone marrow aplasia within 6 months of a documented seronegative (non‐A, non‐B, non‐C) hepatitis, where hepatitis status was characterized as an increase in serum transaminases to at least three times the upper limit of normal.

Telomere length measurement {#ajh24256-sec-0004}
---------------------------

Telomere length (TL) measurements of peripheral blood lymphocytes were performed by fluorescence *in situ* hybridization coupled with flow cytometry (flow‐FISH) [15](#ajh24256-bib-0015){ref-type="ref"} as a part of the clinical diagnostic evaluation by a CLIA‐certified TL testing center (Repeat Diagnostics, North Vancouver, Canada), that provides a reference to respective TL of age‐matched healthy controls.

Lymphocyte subset analysis {#ajh24256-sec-0005}
--------------------------

Lymphocyte subset analysis of patients' peripheral blood was performed by flow cytometry as a part of standard clinical evaluation by the CLIA‐certified CHOP Clinical Immunology Laboratory. Median absolute lymphocyte counts for age‐matched normal controls were obtained from the established reference of immunophenotyping of lymphocyte subpopulations in childhood [16](#ajh24256-bib-0016){ref-type="ref"}.

Sanger sequencing {#ajh24256-sec-0006}
-----------------

Sanger sequencing for inherited mutations in the *TERT* and *TERC* genes was performed by polymerase chain reaction (PCR) amplification of the 16 exons of the *TERT* gene and of the single exon of the *TERC* gene, followed by bi‐directional Sanger sequencing, using standard techniques [17](#ajh24256-bib-0017){ref-type="ref"}. Oligonucleotide sequences were used as previously published [11](#ajh24256-bib-0011){ref-type="ref"}, with minor modification. Genotyping for the two polymorphic variants in *TERT* and *RTEL1* genes was performed similarly; all oligonucleotide sequences are listed in Supporting Information.

Whole exome sequencing (WES) and bioinformatic analysis {#ajh24256-sec-0007}
-------------------------------------------------------

WES was performed on DNA extracted from the patients' bone marrow aspirate and paired skin fibroblast DNA as described previously [18](#ajh24256-bib-0018){ref-type="ref"}, using Qiagen DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) at the BGI\@CHOP High Throughput Sequencing Center. Exome libraries were constructed with Agilent SureSelect All Exon V4 + UTRs kit (Agilent Technologies, Santa Clara, CA). Paired‐end WES to 150X average depth was performed using the Illumina HiSeq 2500 platform, according to the manufacturer\'s recommendations. Constitutional calling on bone marrow--skin biopsy pairs was performed with VarScan2 [19](#ajh24256-bib-0019){ref-type="ref"}, using parameters *--min‐coverage 4,--min‐var‐freq 0.08,--P‐value 0.05,--strand‐filter 1--min‐avg‐qual 20,* with downstream filtering and annotation in SNP & Variation Suite v8.0 (Golden Helix, Bozeman, MT) to identify constitutional variants in the known genes associated with DC: *ACD*, *CTC1, DKC1, NHP2, NOP10, PARN, RTEL1, TERC, TERT, TINF2, USB1, and WRAP53*. All nonsynonymous coding or splice‐site variants were manually curated in Integrative Genomics Viewer [20](#ajh24256-bib-0020){ref-type="ref"}. To determine minor allele frequencies in the population, variants were annotated against databases of genomic variation (dbSNP, 1000Genomes Project, NHLBI GO Exome Sequencing Project, Exome Aggregation Consortium, and the Supercentenarian 17 [21](#ajh24256-bib-0021){ref-type="ref"}, [22](#ajh24256-bib-0022){ref-type="ref"}, [23](#ajh24256-bib-0023){ref-type="ref"}, [24](#ajh24256-bib-0024){ref-type="ref"}, [25](#ajh24256-bib-0025){ref-type="ref"}). To estimate potential impact on protein function, variants were further subjected to *in silico* functional annotation using a panel of five functional prediction algorithms---SIFT [26](#ajh24256-bib-0026){ref-type="ref"}, PolyPhen‐2 [27](#ajh24256-bib-0027){ref-type="ref"}, MutationTaster [28](#ajh24256-bib-0028){ref-type="ref"}, FATHMM [29](#ajh24256-bib-0029){ref-type="ref"}, and MutationAssessor [30](#ajh24256-bib-0030){ref-type="ref"}.

Statistics {#ajh24256-sec-0008}
----------

Fisher\'s exact test was used to compare gender, TL above and below the 1st percentile for age, and disease severity between the two groups (HAA vs. IAA). Wilcoxon test was used to compare age, total lymphocytes counts, CD3^+^ T lymphocytes, CD19^+^ B lymphocytes, CD3^+^CD4^+^ T cells, CD3^+^CD8^+^ T cells, and CD4/CD8 ratios between the two groups. Linear regression was used to compare telomere lengths between the two groups adjusting for patients' age. The telomere lengths in IAA and HAA groups were correlated with total lymphocyte and lymphocyte subset (CD3^+^, CD3^+^ CD4^+^, CD3^+^ CD8^+^ and CD19^+^) counts via the Pearson correlation coefficient. All statistical comparisons were two‐sided and a *P* value \<0.05 was considered statistically significant.

Results {#ajh24256-sec-0009}
=======

Clinical presentation {#ajh24256-sec-0010}
---------------------

Twenty nine consecutively enrolled patients with pediatric‐onset AA were included in this study: 10 had HAA and 19 had idiopathic AA not related to hepatitis (IAA) (Table [1](#ajh24256-tbl-0001){ref-type="table-wrap"}). The median age at diagnosis was 8.0 years (range 1--19 years). AA disease severity was very severe in 6 patients, severe in 21 patients, and moderate in 2 patients. There was no significant difference in age (*P* = 0.982), gender (*P* = 0.450) or AA disease severity (*P* = 0.552) between the HAA and IAA patient groups. In agreement with prior reports [9](#ajh24256-bib-0009){ref-type="ref"}, the median time from the diagnosis of seronegative hepatitis to the development of cytopenias was 3 weeks, ranging from under 1 week to 4 months (Table [2](#ajh24256-tbl-0002){ref-type="table-wrap"}). Transaminases peaked at a median of 2,589 U L^−1^ for alanine aminotransferase (range 865--3,461 U L^−1^) and 2,161 U L^−1^ for aspartate aminotransferase (range 391--6,707 U L^−1^), with total bilirubin peaking at a median of 12.45 milligrams/dL (range 0.9--52 mg dL^−1^). Seven of the ten patients had a diagnostic liver biopsy; one patient underwent an orthotopic liver transplant for acute liver failure, whereas in other patients hepatitis resolved following corticosteroid therapy or was self‐limited.

###### 

Patient Characteristics of Hepatitis‐associated and Idiopathic Aplastic Anemia Patients

  Patient characteristic                     Overall (*n* = 29)   IAA (*n* = 19)   HAA (*n* = 10)   *P* value
  ------------------------------------------ -------------------- ---------------- ---------------- -----------
  Age at diagnosis, y, median (range)        8 (1‐19)             9 (1‐19)         8 (3‐17)         0.982
  **Gender, *n* (%)**                        0.450                                                  
  Female                                     12 (41)              9 (47)           3 (30)           
  Male                                       17 (59)              10 (53)          7 (70)           
  **Disease severity, *n* (%)**              0.552                                                  
  Severe                                     21 (73)              13 (68)          7 (70)           
  Very severe                                6 (21)               3 (16)           3 (30)           
  Moderate                                   2 (7)                2 (11)           0 (0)            
  **Median lymphocyte telomere length**      **0.009**                                              
  ≤1st percentile of age‐matched controls    4                    0                4                
  \>1st percentile of age‐matched controls   25                   19               6                

IAA, idiopathic acquired aplastic anemia, not associated with hepatitis; HAA, hepatitis‐associated acquired aplastic anemia. Y, years. kb, kilobases.

###### 

Clinical Characteristics of Ten Patients With Hepatitis‐associated Aplastic Anemia

  Patient ID   Age (years)   Median TL (kilobases)   Peak ALT (U L^−1^)   Peak AST (U L^−1^)   Total bilirubin (mg dL^−1^)   Liver biopsy performed   Hepatitis to AA interval (months)   AA severity   Cytogenetics   PNH flow cytometry\*   AA therapy
  ------------ ------------- ----------------------- -------------------- -------------------- ----------------------------- ------------------------ ----------------------------------- ------------- -------------- ---------------------- -----------------------
  484.01       8             5.9                     3,461                4,551                25.6                          Yes                      1                                   SAA           Normal         Negative               IST
  466.01       12            6.7                     2,586                1,639                9.3                           Yes                      4                                   VSAA          Normal         Minor (\<1%)           IST
  274.01       5             6.9                     1,607                3,434                11.8                          Yes                      3                                   SAA           Normal         n/a                    Allo‐BMT
  487.01       8             6.9                     1,711                2,296                21.6                          Yes                      1                                   SAA           Normal         Minor (\<1%)           IST
  492.01       10            7.6                     2,592                1,775                13.1                          No                       0.5                                 SAA           Normal         Negative               Allo‐BMT
  412.01       17            8.3                     3,431                6,707                52                            Yes                      Diagnosed concurrently              SAA           Normal         1.40%                  Died prior to therapy
  409.01       7             9.1                     2,814                3,471                19                            Yes                      2                                   SAA           Normal         Negative               Allo‐BMT
  369.01       7             9.2                     3,286                2,025                4.7                           Yes                      Diagnosed concurrently              VSAA          Normal         Negative               Allo‐BMT
  275.01       11            9.4                     865                  391                  1.6                           No                       Diagnosed concurrently              SAA           Normal         Minor (\<1%)           Allo‐BMT
  450.01       3             9.8                     1,030                599                  0.9                           No                       Diagnosed concurrently              VSAA          Normal         Negative               IST

TL, telomere lengths; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAA, severe AA; VSAA, very severe AA; PNH, paroxysmal nocturnal hemoglobinuria; Allo‐BMT, allogeneic bone marrow transplant; IST, immunosuppression therapy. \*, PNH clone size as measured by the % of CD55‐ and CD59‐negative granulocytes.

Patients with hepatitis‐associated aplastic anemia have significantly shorter lymphocyte telomere lengths than patients with idiopathic AA {#ajh24256-sec-0011}
------------------------------------------------------------------------------------------------------------------------------------------

Strikingly, the lymphocyte telomere lengths (TL) were significantly shorter in HAA patients, compared to patients with IAA; on average, TL in HAA patients were 0.9713 kilobases shorter after accounting for the patients' age (*P* = 0.009). Notably, 4 of 10 HAA patients had telomeres at or below the 1st percentile of age‐matched normal controls, within the diagnostic range for telomeropathies [10](#ajh24256-bib-0010){ref-type="ref"}, [31](#ajh24256-bib-0031){ref-type="ref"}; in contrast, none of the nineteen IAA patients in our cohort had TL below the 1st percentile (*P* = 0.009) (Table [1](#ajh24256-tbl-0001){ref-type="table-wrap"}, Fig. [1](#ajh24256-fig-0001){ref-type="fig"}A). None of the HAA patients with very low TL had clinical features of classic DC.

![Disrupted lymphocyte homeostasis in hepatitis‐associated acquired aplastic anemia is associated with short telomeres. A. A scatter plot depicting median telomere length in kilobases (kb) on the *Y* axis, plotted against the patients' age in years on the *X* axis. Values for patients with hepatitis‐associated aplastic anemia (HAA) are shown with white triangles, and those for idiopathic aplastic anemia (IAA) are shown with gray circles. For comparison, values for patients with genetically confirmed dyskeratosis congenita (DC) are shown with black squares. The solid line in the figure indicates the 50th percentile of normal median telomere length for age‐matched controls. The regression lines for HAA and AA patients are shown as a large dashed and small dashed lines, respectively. B. Shown are the lymphocyte counts within the specified lymphocyte subsets in patients with HAA (white triangles), IAA (gray circles), and age‐matched normal controls (white rectangles), including: absolute total lymphocyte count; CD3^+^ T cells; CD3^+^CD4^+^ T cells; CD3^+^CD8^+^ T cells; and CD19^+^ B cells. The horizontal black bars represent the median for each lymphocyte population. For total lymphocytes as well as for all T lymphocyte subsets, HAA patients showed significant differences compared to IAA patients; for each intergroup comparison, the corresponding p‐value is listed above the bracket. C. A scatter plot depicting median telomere length in kilobases (kb) on the *X* axis plotted against the patients' absolute lymphocyte count on the *Y* axis; regression line is shown as a black line. All AA patients are included.](AJH-91-243-g001){#ajh24256-fig-0001}

To ensure that the significantly lower telomere lengths in the HAA patients were not caused by an occult telomere disorder, we used whole exome sequencing to screen three of the four patients with TL at or below the 1st percentile for mutations in known genes associated with DC (Supporting Information Table I) [32](#ajh24256-bib-0032){ref-type="ref"}, [33](#ajh24256-bib-0033){ref-type="ref"}. Although we identified several polymorphic variants (Supporting Information Table II), our analysis revealed no disease‐causing mutations. Two of the three patients carried rare single nucleotide polymorphisms (SNPs) with a minor allele frequency below 1% in the general population [21](#ajh24256-bib-0021){ref-type="ref"}, [22](#ajh24256-bib-0022){ref-type="ref"}, [24](#ajh24256-bib-0024){ref-type="ref"}; these were examined more closely. Patient 484.1 was found to carry two rare variants: heterozygous polymorphism (dbSNP rs35719940) in *TERT* (c.2995G\>A, p.Ala999Thr), with an allele frequency of 0.9% overall and 2% in the European population, as well as a homozygous polymorphism (dbSNP rs190887884) in *RTEL1* (c.2546G\>A, p.Gly849Asp), with an allele frequency of 0.6% overall and 0.99% in the European population; the latter was previously described as a nonsegregating, benign variant in a study of familial interstitial pneumonia [34](#ajh24256-bib-0034){ref-type="ref"}. This patient\'s parents, both in good health, were genotyped and confirmed to be heterozygous carriers of the rs190887884 in *RTEL1*; one of the parents was also confirmed to be a heterozygous carrier of rs35719940 in *TERT* (Supporting Information Fig. 1). Lymphocyte TL measurements of both parents were normal, at 50th percentile of age‐matched normal controls, suggesting that neither variant is disease‐causing. Similarly, patient 487.1 was found to be heterozygous for two rare variants: a polymorphism (dbSNP rs754768798) in *RTEL1* (c.3103C\>T, p.Pro1035Ser) with a reported frequency of 4 in 116296 alleles in the Exome Aggregation Consortium [25](#ajh24256-bib-0025){ref-type="ref"}, as well as a novel variant in *WRAP53* (c.1597G\>A, p.Gly533Ser). *In silico* analysis of functional impact using five independent functional prediction algorithms suggested that both variants are functionally benign (Supporting Information Table II); in agreement, the patient\'s TL repeated at 1 year after diagnosis showed a median lymphocyte TL increased to between the 1st and 10th percentile.

The fourth patient with TL below the 1st percentile underwent an upfront matched related donor bone marrow transplant and maintained follow‐up in our center for only 1 year after transplant. Although we were unable to perform WES due to the lack of sufficient available germline DNA material, we were able to test for germline mutations in *TERT* and *TERC* by Sanger sequencing, with no pathogenic mutations identified. Additionally, the patient\'s pretransplant conditioning contained a high dose alkylating agent, cyclophosphamide at 200 mg kg^−1^, which was tolerated without organ toxicity as evidenced by normal pulmonary and liver function tests at the patient\'s last follow‐up at our center 1 year after transplant. While an uncomplicated transplant course does not completely exclude an occult telomeropathy, the patient\'s complete lack of transplant‐related complications strongly argues against a severe form of an inherited telomere disorder.

For three of the four patients with TL at or below the 1st percentile at diagnosis, lymphocyte TL was repeated 1 year after therapy. The fourth patient was unavailable for lymphocyte TL analysis for reason of having received a bone marrow transplant. Of the three patients who were able to be tested, two patients demonstrated an increase in median lymphocyte TL: median lymphocyte TL increased to between the 1st and 10th percentile in one patient and to ∼50th percentile in the second patient. The third patient remained lymphopenic with TL below the 1st percentile.

Disrupted lymphocyte homeostasis in hepatitis‐associated aplastic anemia is associated with short telomeres {#ajh24256-sec-0012}
-----------------------------------------------------------------------------------------------------------

Because specific subsets and activation states of lymphocytes are associated with distinct telomerase activity [35](#ajh24256-bib-0035){ref-type="ref"}, [36](#ajh24256-bib-0036){ref-type="ref"}, [37](#ajh24256-bib-0037){ref-type="ref"}, we hypothesized that differences in lymphocyte populations associated with the unique inflammatory state of HAA [9](#ajh24256-bib-0009){ref-type="ref"}, [38](#ajh24256-bib-0038){ref-type="ref"} could partly account for the significantly shorter TL in this population, as well as for the subsequent increase in median telomere length in a subset of patients at 1‐year post‐therapy. While both HAA and IAA patients were found to have lower total and B lymphocyte counts than age‐matched normal controls, compared to IAA patients, HAA patients exhibited significantly lower absolute lymphocytes (*P* = 0.0002), CD3^+^ T lymphocytes (*P* = 0.0001), CD4+ and CD8+ T lymphocyte subsets (*P* = 0.0001 and *P* = 0.0048, respectively) (Fig. [1](#ajh24256-fig-0001){ref-type="fig"}B), and, in agreement with prior studies [9](#ajh24256-bib-0009){ref-type="ref"}, [38](#ajh24256-bib-0038){ref-type="ref"}, a significantly decreased CD4/CD8 ratio (*P* = 0.0174) (data not shown). Importantly, the median TL showed a significant correlation with lymphocyte counts (Pearson correlation coefficient 0.47, *P* = 0.0095) (Fig. [1](#ajh24256-fig-0001){ref-type="fig"}C). Of note, all four patients with the sub‐1st percentile telomere lengths appeared to have more severe hepatic dysfunction as evidenced by significant hyperbilirubinemia and marked transaminitis; in contrast, patients with milder hepatic dysfunction, as evidenced by milder hyperbilirubinemia and the clinical decision to forgo a liver biopsy, had higher TL (Table [2](#ajh24256-tbl-0002){ref-type="table-wrap"}).

Discussion {#ajh24256-sec-0013}
==========

Using a combination of lymphocyte TL measurements, WES, and lymphocyte subset analysis, we have shown that patients with HAA have significantly lower lymphocyte TL at diagnosis than patients with idiopathic AA, including 40% of HAA patients with TL below the 1st percentile of age‐matched controls. Our results underline the lack of specificity of lymphocyte TL as a screening test for inherited telomere disorders in HAA, and provide evidence that disrupted lymphocyte homeostasis associated with inflammatory disorders such as HAA can affect lymphocyte TL, limiting its clinical utility in this patient population.

The association of AA with seronegative autoimmune hepatitis is well recognized, with a history of non‐A, B, or C hepatitis present in 5--10% of AA patients [39](#ajh24256-bib-0039){ref-type="ref"}. Although the clinical syndrome of HAA is generally fairly distinct, characterized by marked transaminitis preceding or concurrent with the onset of cytopenias in a previously healthy pediatric or young adult patient [9](#ajh24256-bib-0009){ref-type="ref"}, it can occasionally mimic an occult telomere disorder. Patients with inherited mutations in *TERT* and *TERC* can present with cytopenias in conjunction with severe seronegative hepatitis and hepatic necrosis, which may require liver transplantation [6](#ajh24256-bib-0006){ref-type="ref"}. Similarly, a case of an apparent familial bone marrow failure syndrome presenting as classical HAA has been reported, with the patient\'s course notable for failure to respond to immunosuppressive therapy, progression to myelodysplasia, and subsequent death 44 days post‐transplant due to multiple transplant‐related complications [40](#ajh24256-bib-0040){ref-type="ref"}, suggestive of an undiagnosed telomeropathy. The recognized potential for devastating consequences of a missed occult telomere syndrome [41](#ajh24256-bib-0041){ref-type="ref"} highlights the importance of considering inherited syndromes in the differential diagnosis of HAA. Importantly, our results show that the diagnostic evaluation should thoughtfully incorporate other data beyond the lymphocyte TL measurements. Similar to other inflammatory conditions associated with antigen‐driven replicative exhaustion and telomere shortening [42](#ajh24256-bib-0042){ref-type="ref"}, [43](#ajh24256-bib-0043){ref-type="ref"}, [44](#ajh24256-bib-0044){ref-type="ref"}, HAA has been linked to a variety of lymphocyte abnormalities [9](#ajh24256-bib-0009){ref-type="ref"}, [14](#ajh24256-bib-0014){ref-type="ref"}, and our study demonstrates that lymphopenia and skewed lymphocyte subsets correlate with shorter telomere lengths in HAA.

Limitations of our study include a relatively small sample size. However, AA is a rare disease with an incidence of one to two cases per million, of which HAA comprises a much smaller fraction of 5--10%. Recognizing the rarity of HAA, our study represents one of the largest single‐institution cohorts of HAA. Future systematic studies performed through multi‐institutional collaborations that incorporate a larger patient population will be needed to better define the kinetics of telomere shortening and recovery in HAA, and to delineate other clinicopathologic characteristics that can better define this patient population.

In sum, our finding that abnormally diminished and skewed T cell populations in HAA are associated with very short lymphocyte TL suggests that the disrupted lymphocyte homeostasis intrinsic to the pathogenesis of pediatric HAA [9](#ajh24256-bib-0009){ref-type="ref"}, [14](#ajh24256-bib-0014){ref-type="ref"} may limit the specificity of TL as a screening tool to exclude DC in patients with HAA. Although further studies are needed to elucidate the etiology of shortened lymphocyte telomeres, our results indicate the critical importance of caution in the use of TL measurements to diagnose telomere disorders in patients presenting with hepatitis and bone marrow aplasia.
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